News und Analysen
The Best Dividend King to Buy With $150
Shares of Abbott Laboratories (NYSE: ABT) recently plunged after the company announced its fourth-quarter results. Over the trailing 12 months, the stock is down 16%. Some might choose to stay away
3 Headwinds Facing Pfizer in 2026
Pfizer (NYSE: PFE) is one of the world's largest pharmaceutical companies. It has a long history of innovation and success. Add in a lofty 6.6% dividend yield, and dividend investors are likely to
Where Will AbbVie Be in 5 Years?
In some ways, AbbVie (NYSE: ABBV) isn't the same company it was five years ago. Sure, it's still in the biopharmaceuticals business. However, AbbVie has a new CEO. More importantly, it no longer
Why AT&T Stock Surged This Week
Shares of AT&T (NYSE: T) jumped more than 10% this past week, according to data from S&P Global Market Intelligence.
The wireless carrier delivered an impressive quarterly financial report and
This February, Focus on This Overlooked Money-Making Investing Secret
Last month, millions of people made New Year's resolutions. Many of them have likely already come to a halt. But the experiment I started on Jan. 1 is still going strong, and as the new Voyager
Here's Why Pfizer Stock Is Still a Buy
Pfizer (NYSE: PFE) got a huge boost during the coronavirus pandemic thanks to its COVID-19 vaccine. Since that point, however, investors have soured on the stock, which has lost more than half its
2 No-Brainer Dividend Stocks to Buy Hand Over Fist
Over the past decade, AbbVie (NYSE: ABBV) and Mastercard (NYSE: MA) have produced strong market returns. Their performance is even better once we account for dividends reinvested. That is one of the
CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026
John Walter Hanna Jr., President and CEO of CareDx (NASDAQ:CDNA), directly sold 19,480 shares in multiple open-market transactions on Jan. 21 and Jan. 22, 2026, for a total value of approximately
2 Stocks That Could Soar This Year
In the volatile biotech industry, companies can see their shares soar over relatively short periods on strong clinical progress for exciting pipeline candidates.
That's precisely what could happen
1 AI Stock I'm Buying Before It Goes Parabolic in 2026
In a move that may surprise nobody, artificial intelligence (AI) hyperscalers are planning to double down on their infrastructure spend this year. According to FactSet Research, big tech is forecast
Better Long-Term Buy: This Emerging Player or the Industry Leader?
AbbVie (NYSE: ABBV) is one of the largest pharmaceutical companies in the world. Though its portfolio spans many therapeutic areas, it is particularly well known for its work in immunology, a field
CareDx President and CEO Sells 19,000 Shares for $412,000
John Hanna, President and CEO of CareDx (NASDAQ:CDNA), directly sold 19,480 shares in multiple open-market transactions on Jan. 21, 2026 and Jan. 22, 2026, with an aggregate transaction value of
Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News
David Novack, President & COO of Dynavax Technologies Corporation (NASDAQ:DVAX), exercised 114,000 stock options and immediately sold the resulting shares for a transaction value of approximately
3 Top Dividend Stocks Yielding More Than 4% to Buy Hand Over Fist This Year
Some investors are skeptical of companies with high dividend yields, since it sometimes signals that the dividend may be unsustainable. However, plenty of high-yield dividend stocks look solid
The Hidden AI Winner That Wall Street Analysts Love for 2026
When most people think of artificial intelligence (AI) winners, names like Nvidia or Advanced Micro Devices might come to mind. These are chip designers that are powering key AI tasks like the
Should You Buy Guardant Health Before Feb. 19?
Guardant Health (NASDAQ: GH) is on the rise, in more ways than one.
Shares of the precision oncology company have skyrocketed over the last six months. Guardant Health has also chalked up several
Stock Market Today, Jan. 29: AT&T Climbs as Earnings Confirm Cash Flow Strength
AT&T (NYSE:T), a provider of wireless, broadband, and fixed-line telecom services, closed Thursday at $25.11, up 4.32%. The stock moved higher after analyst upgrades and a strong fourth-quarter 2025
AT&T's Lumen Deal Hides an Opportunity Most Investors Are Missing
Telecom giant AT&T (NYSE: T) agreed to pay $5.75 billion last year to acquire Lumen's fiber business. The deal, which is expected to close early this year, will add 4 million passed locations and 1
Prediction: 2026 Will Be the Year of Vertex Pharmaceuticals
Despite a few setbacks, Vertex Pharmaceuticals (NASDAQ: VRTX) performed pretty well last year, although it lagged the S&P 500. However, things could be very different in 2026. Thanks to several
This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy?
Over the past five years, Novavax (NASDAQ: NVAX), a vaccine maker, lost more than 90% of its market value. Though it succeeded in its goal of launching a coronavirus vaccine, the biotech did so much
Want to Buy the Dip on Software Tech Stocks Like Palantir, Microsoft, and Oracle? Consider This BlackRock ETF.
Last year, technology outperformed the other 10 sectors of the stock market and the S&P 500, delivering a 24.7% total return. A lot of those gains were driven by semiconductor stocks like Nvidia
3 High-Yield Stocks to Buy Hand Over Fist in January
The S&P 500 index offers a paltry 1.1% dividend yield. By that standard, even consumer products giant Procter & Gamble's (NYSE: PG) 2.8% yield looks lofty. Here's why dividend lovers may want to
Why I Keep Buying More Shares of This Amazing Artificial Intelligence (AI) Chip Stock for 2026
In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD) and other AI stocks. To learn more, check out the short video, consider subscribing, and click the special
AMD and Nvidia Stock Investors Got Amazing News from China
In today's video, I discuss recent updates affecting Nvidia (NASDAQ: NVDA), Advanced Micro Devices (NASDAQ: AMD), and other AI stocks. To learn more, check out the short video, consider subscribing,



